UNC1999 is a novel SAM-competitive EZH2/EZH1 inhibitor that has demonstrated efficacy in several cancer models such as leukemia, multiple myeloma and colon cancer [29, 39, 40]. This evidence concerns the gene EZH2 and plasma cell myeloma.